Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.45 |
| ▸ | KDR | P35968 | 7/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.39 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.39 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.39 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8965977 | 0.93 | PIK3CA (0.44) | PIK3CAKDRPIK3CDPIK3CGKMT2A | |
| SCHEMBL8965644 | 0.92 | PIK3CA (0.42) | PIK3CAKDRKMT2ARIPK1CSNK1D | |
| SCHEMBL8965523 | 0.92 | PIK3CA (0.47) | PIK3CAKDRSMN1; SMN2MAOBPIK3CD | |
| SCHEMBL8965909 | 0.91 | PIK3CA (0.42) | PIK3CAKDRSMN1; SMN2MAOBPIK3CD | |
| SCHEMBL8966365 | 0.90 | PIK3CA (0.41) | PIK3CAKDRSMN1; SMN2MAOBPIK3CD | |
| SCHEMBL8965972 | 0.90 | PIK3CA (0.46) | PIK3CAKDRSMN1; SMN2MAOBPIK3CD | |
| SCHEMBL8965525 | 0.90 | PIK3CA (0.41) | PIK3CAKDRSMN1; SMN2MAOBPIK3CD | |
| SCHEMBL8966239 | 0.90 | PIK3CA (0.43) | PIK3CAKDRPIK3CDPIK3CGMEN1 | |
| SCHEMBL8966260 | 0.90 | KDR (0.44) | PIK3CAKDRPIK3CDPIK3CGMEN1 | |
| SCHEMBL8965975 | 0.89 | PIK3CA (0.45) | PIK3CAKDRMAOBPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119948063-A | Bispecific antibodies binding EGFR and B7-H3 | 信达生物制药(苏州)有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-114606306-B | Probe composition, reagent, kit and detection method for detecting mucopolysaccharidosis VII type | 江苏源隆医疗科技有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-117070622-A | Primer group, detection method and application thereof | 深圳市妇幼保健院 | 2023-11-17 | — | — | CN | claimed |
| CN-114606306-A | Probe composition, reagent, kit and detection method for detecting mucopolysaccharide storage disease VII | 江苏源隆医疗科技有限公司 | 2022-06-10 | — | — | CN | claimed |
| US-5538970-A | Treatment of cancer with imidazo-1,2-pyridazin compounds | GLAXO WELLCOME INC. (US) | 1996-07-23 | — | — | US | claimed |
| US-5447956-A | Anticarcinogenic agents | BURROUGHS WELLCOME CO. (US) | 1995-09-05 | — | — | US | claimed |
| US-5380759-A | Methyl N-[6-(3,4,5-trimethoxybenzloxy)imidazo[1,2-b]pyridazin-2-zyl]carbamate used to treat leukemia | BURROUGHS WELLCOME CO. (US) | 1995-01-10 | — | — | US | claimed |
| US-5091531-A | Antitumor agents | BURROUGHS WELLCOME CO. (US) | 1992-02-25 | — | — | US | claimed |
| EP-0305093-A1 | Imidazo(1,2-b)pyridazine derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-03-01 | — | — | EP | claimed |
| JP-1068375-A | — | — | None | — | — | JP | disclosed |
| EP-4732901-A2 | METHODS OF TREATING FABRY DISEASE | Amicus Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4492906-B1 | SYSTEMS AND METHODS FOR MULTI-CONNECTIVITY OPERATION | SHARP KK (JP) | 2026-04-15 | — | — | EP | disclosed |
| US-20260076951-A1 | METHODS OF TREATING FABRY DISEASE IN PATIENTS HAVING RENAL IMPAIRMENT | AMICUS THERAPEUTICS, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-3851105-B1 | MIGALASTAT FOR USE IN TREATING FABRY DISEASE IN PATIENTS HAVING A MUTATION IN THE GLA GENE | AMICUS THERAPEUTICS INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-5447956-A | Anticarcinogenic agents | BURROUGHS WELLCOME CO. (US) | 1995-09-05 | — | — | US | disclosed |
| US-5380759-A | Methyl N-[6-(3,4,5-trimethoxybenzloxy)imidazo[1,2-b]pyridazin-2-zyl]carbamate used to treat leukemia | BURROUGHS WELLCOME CO. (US) | 1995-01-10 | — | — | US | disclosed |
| US-5371219-A | Antitumor agents | BURROUGHS WELLCOME CO. (US) | 1994-12-06 | — | — | US | disclosed |
| EP-0305093-B1 | Imidazo(1,2-b)pyridazine derivatives | WELLCOME FOUND (GB) | 1994-04-06 | — | — | EP | disclosed |
| US-5091531-A | Antitumor agents | BURROUGHS WELLCOME CO. (US) | 1992-02-25 | — | — | US | disclosed |
| EP-0305093-A1 | Imidazo(1,2-b)pyridazine derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076951-A1 | METHODS OF TREATING FABRY DISEASE IN PATIENTS HAVING RENAL IMPAIRMENT | MME, ERP44, HSPA5 | PIK3CA 3906/4885KDR 3668/4885SMN1; SMN2 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.